Abstract
The major issue of cancer chemotherapy is the adverse effect, which is elicited by the systemic exposure of the anticancer agents. The application of DDS technology into anticancer agents is able to inhibit non-selective distribution and to increase accumulation into tumor tissue, thus it can decrease systemic adverse effects and improve therapeutic effect of the anticancer agents. To design the formulation of drugs, it must be considered that the drug products can produce the best performance on clinical settings rather than on animal experiments. However, the translation of the knowledge obtained from animal experiment into the development of the best formulation for clinical usage is quite difficult because there are some discrepancies between human clinical cancer treatments and the tumor-bearing animal experiments. Herein, we will introduce the factors to care on the development of DDS products, especially liposomal formulations, for the treatment of cancer.
